Clinical Study
Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma
Table 3
Most common or serious hematologic and
nonhematologic toxicities.
| | Toxicity | Grade 2 | | Grade 3 | | Grade 4 | | |
No. | %
|
No. | %
|
No. | %
|
| | Hematologic | | | | | | | | Neutropenia
|
2 | 8
|
1 | 4
| | | | Thrombocytopenia | 3
|
13 | 1
|
4 | | | | Anemia
|
2 | 8
|
1 | 4
| | | | Non-hematologic | | | | | | | | Nausea
|
8 | 33
| | | | | | Emesis | 8
|
33 | 2
|
8 | | | | Fatigue
|
12 | 50
|
1 | 4
| | | | Neurologic toxicity | 5
|
21 | 3
|
12 | | | | Constipation
|
10 | 42
| | | | | | Anorexia | 5
|
21 | | | | | | Edema
|
3 | 13
| | | | |
|
|
